# Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

> **NCT05923905** · PHASE4 · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Sporadic and Familial Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** FB1006
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05923905
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-18
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923905, "Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05923905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*